Aarti Industries Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/x7kaquzdszrakedx0xdccsux.pdf

Key Takeaways


Demand Environment & Volume Outlook

Rajendra Gogri: "Currently, at least Q1, definitely, there is pressure because of the inventories. And as we mentioned, it will be progressively that I think the situation will improve, i.e., quarter-on-quarter."

Financial Performance & Margin Walk


Capex & Capacity Expansion

Rajendra Gogri: "I am excited with the upcoming opportunities in the chemical value-chain and truly believe that this is a 'Golden Decade' for us."

Competitive Dynamics & End-Market Risks

Rajendra Gogri: "Because in general, there will be a fear of higher energy cost in Europe. As far as the existing manufacturing facility in Europe is concerned, I think, definitely because of the decrease in energy prices in Europe, it will benefit them. But on a long-term basis, the energy intense products' growth in Europe will be curtailed."

Long-Term Contracts & Specialty Chemical Blocks


Guidance & Commitments

CommitmentSpecificsTimeline
Volume growth~25% volume growth expectedFY24
EBITDA growth~15% EBITDA growth expected (lower than volume growth due to nonregular market mix)FY24
EBITDA CAGR25% EBITDA CAGR guidance maintainedFY24 & FY25
CapexCombined capex of ₹3,000 cr (~₹1,500 cr annually)FY24 & FY25
NCB expansion commercializationPlant commercialized, volumes to startQ1 FY24 (commercialization), Q2 FY24 (volumes)
Contract 1 utilization rampMove from 20-25% to 30-50% utilizationFY24
Contract 1 utilization rampReach 70% utilizationFY25
Contract 3 utilization rampReach 60-70% utilizationFY25
Nonregular market margin recoveryVolume going to nonregular market to correct, providing additional EBITDA upliftFY25
Zone 4 chloro-toluene and multipurpose plantsCommissioning to start; major volume growth from FY26 onwardsFY25 (commissioning start)
Acid division capacity expansionCapacity expansion by ~22%End-FY24 / early FY25
Ethylation plant capacityTriple capacity, commissioningFY25
Operating EBITDA guidance₹1,700 cr operating guidance maintainedFY25

Key Metrics

MetricQ4 FY23
Revenue₹1,826 cr, +11% YoY; exports contributed over 48%
EBITDA₹252 cr, vs ₹262 cr in Q4 FY22
EBITDA margin13.8%, vs 15.1% in Q4 FY22 (per an analyst's math)
Profit after tax₹149 cr, vs ₹145 cr in Q4 FY22
FY23 revenue₹7,283 cr, +17% YoY
FY23 EBITDA₹1,089 cr, +19% over normalised EBITDA of ₹919 cr in FY22
FY23 PAT₹545 cr
FY23 capexover ₹1,300 cr
FY24–25 annual capex target₹1,500 cr per year, combined ₹3,000 cr over two years
FY24 volume growth guidance~25%, with EBITDA growth lower at around 15% as part of volumes go to non-regular markets
FY24–25 EBITDA CAGR guidance25%, unchanged; FY25 EBITDA guidance of ₹1,700 cr maintained
Nitrochlorobenzene production18,842 MT
Hydrogenation production3,315 TPM
Nitro-Toluene production6,130 MT
PDA production348 TPM
Exports share (FY23)~48% of total revenues
Maintenance shutdown impact~₹10 cr in higher costs, with some volume impact from lower operating days
Long-term contract 1 utilization~20% currently, expected to reach 30–50% in FY24
Long-term contract 3 utilization target (FY25)60–70%
Non-regular market margin differential10–15% lower gross margin vs regular markets
Non-regular market volume share~5–10% of total basket
Cash conversion cycle (FY23)~110 days
Tax rate guidance (FY24)15–17%
Total dividend per share (FY23)₹2.50, 50% of face value
Debt repayment obligation (FY24)~₹350 cr, evenly spread across quarters
Bank line utilization₹1,400–1,500 cr out of ₹1,800–2,000 cr CC lines